AHA: Mavacamten May Treat Hypertrophic Cardiomyopathy

THURSDAY, Nov. 12, 2020 -- Compared with placebo, mavacamten (Mava), a novel inhibitor of cardiac myosin, for 30 weeks leads to improvement in left ventricular (LV) hypertrophy and markers of left-sided filling pressures in patients with obstructive...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news